Mental health providers in Central Illinois offering ketamine say it has changed patients' lives for the better. Still, only ...

The nasal spray has been administered to more than ... In 2023, the FDA warned of potential risks associated with ketamine treatments. “Known safety concerns associated with the use of ketamine ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

In 2019, the Food and Drug Administration approved esketamine (Spravato), a nasal spray for treatment-resistant depression. Research indicates that ketamine therapy helps individuals who did not ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

When Therapy Alone Isn't Enough, Options Like TMS and SPRAVATO® Provide Additional Relief OAK BROOK, Ill., April 8, 2025 ...

Tasman Therapeutics, Inc. (Tasman) has announced plans to raise $175 million in Series A funding to support the late-stage clinical development and eventual commercialization of R-107. This innovative ...

Picture: Neville Barrett / IMAS – A portion of the $1.8 billion spend over five years on new Pharamaceutical Benefit Scheme medications towards esketamine – a nasal spray ketamine for ...

In 2019, VistaGen reported that its ketamine-like drug AV-101B failed ... VistaGene meanwhile is also developing PH10, another pherine nasal spray heading for a phase 2b study in MDD.

It comes in an easy-to-use nasal spray, and as a pre-filled injection ... methamphetamine and MDMA), ketamine and counterfeit pharmaceuticals, due to the risk of drugs being mixed with something else ...